The U.S. Food and Drug Administration approved Vizamyl
(flutemetamol F 18 injection), a radioactive diagnostic drug for use
with positron emission tomography (PET) imaging of the brain in adults
being evaluated for Alzheimer's disease (AD) and dementia.
Dementia
is associated with diminishing brain functions such as memory,
judgment, language and complex motor skills. The dementia caused by AD
is associated with the accumulation in the brain of an abnormal protein
called beta amyloid and damage or death of brain cells. However, beta
amyloid can also be found in the brain of patients with other dementias
and in elderly people without neurologic disease.
Vizamyl works by
attaching to beta amyloid and producing a PET image of the brain that
is used to evaluate the presence of beta amyloid. A negative Vizamyl
scan means that there is little or no beta amyloid accumulation in the
brain and the cause of the dementia is probably not due to AD. A
positive scan means that there is probably a moderate or greater amount
of amyloid in the brain, but it does not establish a diagnosis of AD or
other dementia. Vizamyl does not replace other diagnostic tests used in
the evaluation of AD and dementia.
“Many Americans are evaluated
every year to determine the cause of diminishing neurologic functions,
such as memory and judgment, that raise the possibility of Alzheimer’s
disease,” said Shaw Chen, M.D., deputy director of the Office of Drug
Evaluation IV in the FDA’s Center for Drug Evaluation and Research.
“Imaging drugs like Vizamyl provide physicians with important tools to
help evaluate patients for AD and dementia.”
Vizamyl is the
second diagnostic drug available for visualizing beta amyloid on a PET
scan of the brain. In 2012, FDA approved Amyvid (Florbetapir F 18
injection) to help evaluate adults for AD and other causes of cognitive
decline.
Vizamyl’s effectiveness was established in two clinical
studies comprised of 384 participants with a range of cognitive
function. All participants were injected with Vizamyl and were scanned.
The images were interpreted by five independent readers masked to all
clinical information. A portion of scan results were also confirmed by
autopsy.
The study results demonstrate that Vizamyl correctly
detects beta amyloid in the brain. The results also confirm that the
scans are reproducible and trained readers can accurately interpret the
scans. Vizamyl’s safety was established in a total of 761 participants.
Vizamyl
is not indicated to predict the development of AD or to check how
patients respond to treatment for AD. Vizamyl PET images should be
interpreted only by health care professionals who successfully complete
training in an image interpretation program. The Vizamyl drug labeling
includes information about image interpretation.
Safety risks
associated with Vizamyl include hypersensitivity reactions and the risks
associated with image misinterpretation and radiation exposure. Common
side effects associated with Vizamyl include flushing, headache,
increased blood pressure, nausea and dizziness.
